Western University

Scholarship@Western
Paediatrics Publications

Paediatrics Department

1-1-2016

β-cell
-cell insulin receptor deficiency during in utero development
induces an islet compensatory overgrowth response
Mark Trinder
Children's Health Research Institute, London, ON

Liangyi Zhou
Children's Health Research Institute, London, ON

Amanda Oakie
Children's Health Research Institute, London, ON

Matthew Riopel
Children's Health Research Institute, London, ON

Rennian Wang
Children's Health Research Institute, London, ON, rwang@uwo.ca

Follow this and additional works at: https://ir.lib.uwo.ca/paedpub

Citation of this paper:
Trinder, Mark; Zhou, Liangyi; Oakie, Amanda; Riopel, Matthew; and Wang, Rennian, "β-cell insulin receptor
deficiency during in utero development induces an islet compensatory overgrowth response" (2016).
Paediatrics Publications. 2744.
https://ir.lib.uwo.ca/paedpub/2744

Oncotarget, Vol. 7, No. 29

www.impactjournals.com/oncotarget/

Research Paper: Pathology

β-cell insulin receptor deficiency during in utero development
induces an islet compensatory overgrowth response
Mark Trinder1,2,*, Liangyi Zhou1,3,*, Amanda Oakie1,3, Matthew Riopel1 and Rennian
Wang1,2,4
1

Children’s Health Research Institute, London, Ontario, Canada

2

Departments of Physiology & Pharmacology, University of Western Ontario, London, Ontario, Canada

3

Department of Pathology, University of Western Ontario, London, Ontario, Canada

4

Department of Medicine, University of Western Ontario, London, Ontario, Canada

*

These authors have contributed equally to this study

Correspondence to: Rennian Wang, email: rwang@uwo.ca
Keywords: inducible MIP-βIRKO, fetal pancreas, β-cell proliferation, islet vasculature, Pathology Section
Received: October 28, 2015

Accepted: June 12, 2016

Published: June 30, 2016

Abstract
The presence of insulin receptor (IR) on β-cells suggests that insulin has an
autocrine/paracrine role in the regulation of β-cell function. It has previously been
reported that the β-cell specific loss of IR (βIRKO) leads to the development of
impaired glycemic regulation and β-cell death in mice. However, temporally controlled
βIRKO induced during the distinct transitions of fetal pancreas development has
yet to be investigated. We hypothesized that the presence of IR on β-cells during
the 2nd transition phase of the fetal murine pancreas is required for maintaining
normal islet development. We utilized a mouse insulin 1 promoter driven tamoxifeninducible Cre-recombinase IR knockout (MIP-βIRKO) mouse model to investigate
the loss of β-cell IR during pancreatic development at embryonic day (e) 13, a phase
of endocrine proliferation and β-cell fate determination. Fetal pancreata examined
at e19-20 showed significantly reduced IR levels in the β-cells of MIP-βIRKO mice.
Morphologically, MIP-βIRKO pancreata exhibited significantly enlarged islet size
with increased β-cell area and proliferation. MIP-βIRKO pancreata also displayed
significantly increased Igf-2 protein level and Akt activity with a reduction in
phospho-p53 when compared to control littermates. Islet vascular formation and
Vegf-a protein level was significantly increased in MIP-βIRKO pancreata. Our results
demonstrate a developmental role for the β-cell IR, whereby its loss leads to an islet
compensatory overgrowth, and contributes further information towards elucidating
the temporally sensitive signaling during β-cell commitment.

INTRODUCTION

or insufficient insulin secretion, the levels of IR and
associated downstream signaling pathways are perturbed
[6]. In vitro experiments with the mouse insulinoma
(MIN6) cell line support the importance of IR function
in β-cell physiology, where knockdown of IR expression
resulted in dysregulation of over 1500 genes [7]. Notable
cellular functions regulated by autocrine/paracrine β-cell
insulin signaling include insulin production and glucosestimulated insulin secretion [8]. β-cell IR signaling is
required in vivo for adaptive islet hyperplasia in response
to pancreatic injury and insulin resistance [9], and can

The insulin receptor (IR) is a receptor tyrosine
kinase with widespread expression that promotes glucose
uptake to peripheral tissue in response to secreted insulin
from the pancreatic β-cells [1]. IR signaling is also
implicated in cellular growth, differentiation, survival, and
metabolism [2-4], and expression of IR in β-cells is critical
for the maintenance of euglycemia and islet survival
[5]. In patients with type 2 diabetes mellitus, a disease
characterized by hyperglycemia due to insulin insensitivity
www.impactjournals.com/oncotarget
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enhance rescue from a hyperglycemic state, as seen in
diabetic rats transplanted with rat insulinoma (INS-1)
cells overexpressing human IR [10]. Alternatively, adult
mice with β-cell specific IR knockout (βIRKO) displayed
progressive impairments in glucose-stimulated insulin
secretion, glucose tolerance, and maintenance of β-cell
mass [11]. Although βIRKO mice have been reported to
appear phenotypically normal at birth [9, 11], fetal and
newborn mice with insulin deficiency exhibited increased
islet size and proliferation associated with increased
pancreatic capillary density and decreased islet apoptosis
[12]. Taken together, insulin/IR signaling in β-cells could
be an important regulator of islet development prenatally
and critical for postnatal maintenance of β-cell function.
Therefore, further investigation of IR activity in β-cells is
essential to better understand the pathogenesis of diabetes
and areas of interest for potential therapeutics.
Pancreatic development requires temporal regulation
of both transcription factor expression and external
signaling pathways to generate physiologically functional
adult islets [13, 14]. In particular, the structural homology
between the IR and insulin-like growth factor 1 receptor
(Igf-1r) enables compensation between the two receptors,
allowing β-cells to utilize overlapping signaling pathways
to mediate similar functions [15]. This is particularly
prominent during fetal development [16]. However, the
temporal importance of IR signaling on the prenatal levels
of transcription factors and metabolic proteins necessary
for islet, and more specifically, β-cell differentiation,
proliferation, maturation, and survival has yet to be
sufficiently investigated. Thus, we proposed to determine
if β-cell IR is an essential regulator of β-cell development
to reconcile conflicting findings from the aforementioned
adult βIRKO [11] and fetal insulin [12] knockout studies,
and investigate potential adaptive signaling from the
homologous Igf-1r. This is the first study to investigate the
temporal role of the β-cell IR on the 2nd transition period
of fetal β-cell development by utilizing the mouse insulin
1 promoter to drive tamoxifen-inducible Cre-recombinase
(MIP-CreER) expression in the β-cell IR knockout (MIPβIRKO) mouse model. Our results demonstrate that β-cell
specific loss of IR during fetal β-cell development results
in islet overgrowth due to significantly elevated levels of
Igf-2, phospho-Akt and Vegf-a signals with associated
β-cell replication.

and fate determination. To confirm that the IR knockout
was specific to pancreatic β-cells, MIP-Cre+ mice were
first crossed with a B6.Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J
reporter strain. Fluorescence from the tdTomato reporter
was specific to pancreatic β-cells (Figure 1B) and was not
detected in the brain and other tissues, similar to results
seen in other recent reports [17, 18]. The genotypes of
mice were determined using PCR products of both the IR
and MIP-CreER genes (Figure 1C, Supplemental Table
1). Experimental MIP-βIRKO (MIP-CreER+;IRfl/fl) mice
were positive for both 313bp IRfl/fl and 268bp MIP-CreER+
(Figure 1C); heterozygous IR (IRfl/+, 313bp and 279bp)
(MIP-CreER+;IRfl/+) mice were excluded. Knockout of
IR in β-cells was confirmed by western blot analyses and
depicted a significant reduction in IR protein level (~75%
lost) in MIP-βIRKO pancreata (p < 0.05 vs. controls;
Figure 1D). Reduced IR staining in insulin+ β-cells of
MIP-βIRKO mouse islets was also evaluated by double
immunofluorescence staining (p < 0.001 vs. control,
Figure 1E).

Fetal MIP-βIRKO pancreas display an islet
hyperplastic growth response
Body weight and blood glucose for each control
and MIP-βIRKO fetus were determined at the time of
dissection (e19-20), with results indicating a similar
general phenotype between the two studied groups
(Supplementary Figure 1). In addition, there was no
significant difference in circulating plasma insulin levels
or insulin content from pancreatic tissue between control
and MIP-βIRKO fetal mice (Supplementary Figure
2). Immunofluorescence staining of fetal MIP-βIRKO
pancreatic sections revealed a higher total number of
enlarged islets per pancreatic section (Figure 2A), and
morphometric analyses revealed a 1.8-fold increase in islet
density (number of islets per mm2 of pancreatic sections)
in fetal MIP-βIRKO pancreata (Figure 2B). The mean
islet area (μm2) (p < 0.05; Figure 2C), percent islet area
(percent total islet area over total pancreatic section area;
p < 0.01; Figure 2D), and percent β-cell area (percent total
insulin+ area over total pancreatic section area; p < 0.001;
Figure 2E) were significantly increased in the fetal MIPβIRKO pancreas when compared to control pancreata.
In contrast, α-cell area (percent total glucagon+ area to
total pancreatic section area) did not differ between MIPβIRKO and control groups (Figure 2F) with no alteration
of α- and β-cell distributions (Figure 2H), suggesting that
the β-cell specific IR knockout does not affect α-cells
and islet structure. Furthermore, no changes were noted
regarding somatostatin+- and pancreatic polypeptide+-cell
populations in the islets (Supplementary Figure 3).
To determine if islet changes in MIP-βIRKO
pancreata were due to increased islet number or due to
larger islet sizes, we tallied the size distribution of islets

RESULTS
Characterization of MIP-βIRKO knockout mice
We investigated the temporal role of β-cell IR
knockout on the 2nd transition period of fetal β-cell
development (Figure 1A), a crucial stage of pancreatic
development characterized by endocrine cell proliferation
www.impactjournals.com/oncotarget
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Fetal MIP-βIRKO increase β-cell proliferation
with no change in apoptosis

in both controls and MIP-βIRKO islets according to a
previously established method [12]. We observed that
MIP-βIRKO pancreata had a significantly decreased small
islet population ( < 1000 μm2) and increased percentage of
large islets ( > 10000 μm2) compared to controls (Figure
2G).

To deduce a potential explanation for the islet
growth response, we evaluated β-cell proliferation,
death, and neogenesis in MIP-βIRKO mice. Double
immunofluorescence staining for insulin and Ki67

Figure 1: Confirmation of the fetal MIP-βIRKO mouse model. A. Experimental model schematic with reference timeline
of important events during islet development. B. Immunofluorescence image of Cre recombinase expression within pancreatic β-cells
of MIP-Cre+, but not MIP-Cre-, mouse islets following cross-breeding to a B6.Cg-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J reporter strain. Scale
bars: 25 μm (pancreas) and 5 μm (islets). C. Genotypes of fetal mice were determined by PCR of the IR and MIP-CreER genes, followed
by subsequent gel electrophoresis. D. Western blotting demonstrated a significant reduction in insulin receptor (IR) protein level of fetal
MIP-βIRKO pancreata relative to controls (n = 3-4). IR protein level was normalized to calnexin and expressed as fold vs. controls.
Representative blotting is shown. E. Representative double immunofluorescence images and quantification of IR+ β-cells in MIP-βIRKO
relative to control pancreatic sections. Scale bar: 50 μm. White bar, control group; black bar, MIP-βIRKO group. Data are expressed as
means ± SEM. *p < 0.05, ***p < 0.001 vs. controls. e = embryonic day.
www.impactjournals.com/oncotarget
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Figure 2: Fetal MIP-βIRKO mice display an islet hyperplastic growth response. A. Representative immunofluorescence

image depicting the expanded population of β-cells (red) within fetal MIP-βIRKO pancreata compared to controls. Scale bar: 200 μm.
Morphometric analysis of B. islet density (islets/mm2), C. mean islet area, D. percent islet area, E. percent β-cell area, and F. percent α-cell
area relative to whole pancreatic section area. G. Quantification of different islet sizes. White bars, control group; black bars, MIP-βIRKO
group. Data are expressed as means ± SEM (n = 5-6). *p < 0.05, **p < 0.01 vs. controls. H. Representative double immunofluorescence
images for glucagon (green) and insulin (red) staining in the islets of control and MIP-βIRKO mice. Scale bar: 50 μm. Nuclei were labeled
with DAPI (blue).
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was used to quantify the proliferating insulin+ cells.
Staining showed that Ki67+/insulin+ co-localization was
significantly higher (2.4-fold) in MIP-βIRKO pancreata
compared to controls (p < 0.01, Figure 3A). During
both fetal and postnatal development, islet neogenesis is
initiated from the pancreatic ductal epithelium [19, 20].
As an indicator for islet neogenesis, we evaluated the
number of ductal cells displaying early commitment to
the β-cell lineage by dual labeling of Pan-CK with Pdx-1
(marker for pancreatic progenitors) or insulin (Figure 3B,
3C). The percentage of Pan-CK+ cells expressing nuclear
Pdx-1 showed no significant difference between MIPβIRKO (7%) and control (8%) pancreata (Figure 3B). A
similar result was observed for the percentage of insulin+
ductal cells (Figure 3C). These findings suggest that the
islet growth seen in MIP-βIRKO mice is likely attributed
to the increased replication of pre-existing β-cells, rather
than ductal-to-islet neogenesis.
To assess the possibility that decreased apoptosis
of developing islet cells could also contribute to the islet
compensatory response seen in MIP-βIRKO mice, a
TUNEL assay was performed. The percentage of insulin+
cells labeled by TUNEL in MIP-βIRKO and control
pancreas was similar (Figure 3D). Western blot analyses
also revealed no difference in caspase-3 cleavage between
MIP-βIRKO and control pancreata (Figure 3E). This data
indicates that the enriched β-cell population of the MIPβIRKO pancreas is not due to decreased β-cell apoptosis.

βIRKO islets (Figure 4F).

Fetal MIP-βIRKO islets show increased Vegf-a
levels with enriched islet-vasculature
We further evaluated whether up-regulation of
Igf-2 and Akt signaling could enhance islet Vegf-a
levels, a major factor associated with increased islet
growth [22], and islet vascularization in the developing
fetal pancreas. We found that MIP-βIRKO islets had
elevated pancreatic Vegf-a protein levels as determined
by immunofluorescence (Figure 5A) and western blotting
(p < 0.01 vs. control islets; Figure 5B). Morphological
quantification of islet vascularization (Figure 5C) was
performed by measuring the PECAM-1+ area, islet
capillary density, and average capillary diameter. The
percentage of islet PECAM-1+ area over islet area (p <
0.01; Figure 5D) and islet capillary density (number of
islet capillary per islet area) (p < 0.05; Figure 5E) were
significantly increased in MIP-βIRKO mice compared
to controls. No change in the average islet capillary size
between MIP-βIRKO and control groups was observed
(Figure 5F). In accordance with these findings, MIPβIRKO mice demonstrated increased islet angiogenesis,
as opposed to enlargement of pre-existing capillaries.

MIP-βIRKO at 2nd developmental transition stage
does not affect early β-cell identity

Fetal MIP-βIRKO islets show enhanced
replication and pro-survival signaling pathway
activity

Previous studies have shown that impairments to
the IR-signaling pathway result in reduced expression
and nuclear-to-cytoplasmic translocation of important
β-cell transcription factors, notably seen with factors
Pdx-1 and MafA [7, 9]. Therefore, we employed double
immunostaining on whole fetal pancreatic tissue sections
to investigate potential dysregulation of transcription
factors critical for development and maintenance of β-cell
identity and function. Qualitative observation revealed
that approximately all insulin+ cells possessed nuclear
Pdx-1, Nkx6.1, Islet-1 and MafA (Figure 6) in both MIPβIRKO and control groups. Despite the presence of larger
islets in MIP-βIRKO mice, we observed similar intensity
and membrane-localization of Glut-2 staining in the
insulin+ cells of MIP-βIRKO and control islets (Figure 6).
These results suggest that β-cell identity in MIP-βIRKO
islets is maintained throughout fetal development and is
independent from β-cell IR loss at the 2nd transitional stage
of islet development.

We next investigated the possible mechanistic
link between IR and Igf-1r signaling cascades relevant
to enlarged islets in the fetal MIP-βIRKO pancreas.
The PI3K/Akt signaling pathway plays a critical role in
the regulation of β-cell replication [21]. We observed
significantly increased phospho-Akt (S473) levels in fetal
MIP-βIRKO pancreata compared to controls (p < 0.05;
Figure 4A). In line with up-regulation of phospho-Akt, a
significantly reduced level of phoshpo-p53 (S15), a marker
for proapoptotic p53, was also observed in MIP-βIRKO
pancreata relative to controls (p < 0.05; Figure 4B). To
determine whether the developmental compensation for
impaired β-cell IR signaling could be mediated by the
action of the homologous Igf-1r signaling pathway, the
levels of pancreatic Igf-1 and Igf-2 were examined. Igf-2
protein levels were significantly elevated in the pancreas
of fetal MIP-βIRKO mice compared to controls (p < 0.01;
Figure 4C), with an observable increase in Igf-2 staining
intensity in MIP-βIRKO islets (Figure 4D). In contrast,
both control and MIP-βIRKO fetal islets had low levels of
Igf-1 (Figure 4E). Pancreatic immunohistochemistry also
demonstrated stronger staining-intensity of Igf-1r in MIPwww.impactjournals.com/oncotarget

DISCUSSION
To evaluate the in vivo role of β-cell IR activity
during the 2nd transition phase of pancreatic endocrine
development, we utilized a conditional and temporal MIPβIRKO mouse model. We found that the fetal MIP-βIRKO
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Figure 3: Fetal MIP-βIRKO mice show increased β-cell proliferation with no change in apoptosis. Representative double

immunofluorescence images: A. Ki67/insulin, B. pan-CK/Pdx-1, C. pan-CK/insulin, and D. TUNEL/insulin of MIP-βIRKO and control
pancreatic sections. Nuclei stain, DAPI (blue). White arrows indicate double positive cells. Scale bar: 50 μm. Quantification of Ki67+
β-cells, Pdx1+/Pan-CK+ cells, insulin+/Pan-CK+ cells and β-cell apoptosis in MIP-βIRKO islets relative to controls. E. Western blot analysis
of cleaved caspase-3 (clv-casp 3) and total caspase-3 (t-casp 3). Data is normalized to T-Casp 3 and expressed as fold change to controls.
White bars, control group; black bars, MIP-βIRKO group. Data are expressed as means ± SEM (n = 4-5). ***p < 0.01 vs. controls.
www.impactjournals.com/oncotarget
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Figure 4: Fetal MIP-βIRKO islets have enhanced replication and pro-survival signaling pathway activity. Western blot
analyses of phospho-S473 Akt (P-Akt) and total Akt (T-Akt) (A., n = 4), phospho-S15 p53 (P-p53) and total p53 (T-p53) (B., n = 3-4), and
Igf-2 protein level (C., n = 5-13) in fetal pancreata from MIP-βIRKO and control mice. Representative blotting images are shown. White
bar, control group; black bar, MIP-βIRKO group. Data are expressed as means ± SEM. *p < 0.05, **p < 0.01 vs. controls. Representative
immunohistochemical images for D. Igf-2, E. Igf-1, and F. Igf-1r staining of MIP-βIRKO and control pancreatic sections. Nuclei were
counterstained with hematoxylin. Scale bar: 50 μm.
www.impactjournals.com/oncotarget
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mouse pancreas displays significantly increased mean islet
and β-cell area, mainly attributed to enhanced pre-existing
β-cell replication rather than islet neogenesis or apoptosis.
The contribution of islet overgrowth phenomena is
potentially associated with significantly enhanced Igf2 production via Igf-1r in islets, with corresponding

increased Akt phosphorylation, and enriched islet
vasculature due to increased Vegf-a production (Figure
7). Our results indicate the abrupt interruption of typical
autocrine/paracrine β-cell insulin signaling during the 2nd
transitional phase of pancreatic endocrine development
leads to an islet compensatory overgrowth.

Figure 5: Fetal MIP-βIRKO islets show enhanced islet vascularization. Representative double immunofluorescence images for
A. Vegf-a or C. PECAM-1 (green) with insulin (red), and nuclei stain DAPI (blue), of MIP-βIRKO and control pancreatic sections. Scale
bar: 50 μm. B. Western blotting analysis of Vegf-a protein level in fetal pancreas of MIP-βIRKO and control mice (n = 3-5). Representative
blotting image is shown. Quantitative analyses of D. percent PECAM-1+ area in the islets, E. islet capillary density and F. average islet
capillary size in MIP-βIRKO and controls pancreata. White bars, control group; black bars, MIP-βIRKO group. Data are expressed as
means ± SEM (n = 4-5). *p < 0.05, **p < 0.01 vs. controls.
www.impactjournals.com/oncotarget
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Figure 6: β-cells of fetal MIP-βIRKO islets display typical markers of β-cell identity and function. Representative double

immunofluorescence images for Pdx-1, Nkx6.1, Isl-1 and Glut-2 (green) with insulin (red), and nuclei stain DAPI (blue), of MIP-βIRKO
and control pancreatic sections. Immunohistochemical staining for MafA (red in nuclei). Scale bar: 50 μm.

www.impactjournals.com/oncotarget
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The transcription factors Pdx-1, Nkx6.1, Isl-1,
and MafA are essential for early pancreatic endocrine
development, maintenance of β-cell identity, and
regulation of β-cell function in mature islets, while Glut2
is necessary for glucose uptake in β-cells and regulates
the appropriate insulin release response [23-26]. Similar
to previous studies that examined a non-inducible βIRKO
mouse model [11], we did not observe any evidence for
alteration of β-cell identity in fetal MIP-βIRKO pancreata
as demonstrated by insulin+ cells co-localizing to nuclear
Pdx-1, Nkx6.1, Isl-1, MafA and membrane Glut2.
Although previous IRKO studies suggest that the β-cell IR
plays an insignificant role in fetal islet development [9, 11],
the discrepancy between results from other studies and the
findings presented in our own may be due to the following:
(1) knockout timing during development, (2) missing indepth characterization of islet morphology in prior reports,
and (3) the previous utilization of the alternative rat
insulin 2 promoter to drive Cre-recombinase expression
specifically in β-cells [9, 11]. This is important because
mice expressing Cre-recombinase via the rat insulin 2
promoter show ectopic Cre-recombinase expression in the
brain [27], which is a key region for endocrine pancreatic
regulation [28]. High-resolution microscopy analysis of a
reporter line has determined that the MIP-CreER mouse
model used in this study does not drive the excision of
floxed genes in the central nervous system [17, 29]. It is
acknowledged that ectopic human growth hormone (hGH)

was highly expressed in MIP-CreER islets independent of
tamoxifen administration [17], which might promote the
paracrine effects of hGH-induced serotonin expression
[30]. To clarify this possible influence on our results, we
examined the islet morphologies of MIP-CreER negative
IR knockout (MIP-CreER-;IRfl/fl) and MIP-CreER positive
wide-type (MIP-CreER+;IR+/+) mouse pancreas during
in utero development and did not detect any differences
between these two groups. Thus, the findings indicate no
major effect of hGH at the fetal development stage.
Histological analyses of islets demonstrated that
fetal MIP-βIRKO β-cells have significantly increased
proliferative capacity in vivo over their control β-cell
counterparts. Murine β-cell neogenesis begins at e9 and
remains active for the first three weeks after birth [31], and
by the end of the 3rd transition stage is rapidly diminished
and replaced by β-cell replication. We observed similar
islet neogenesis from epithelial ducts in both MIP-βIRKO
and control pancreata. Therefore, the islet compensatory
response observed in MIP-βIRKO mice is likely a
result of enhanced β-cell replication and expansion of
individual islets as opposed to β-cell neogenesis. This is
congruent with the observation of increased Akt activity,
an important regulator of β-cell proliferation and antiapoptotic signaling [21], in fetal MIP-βIRKO pancreata.
The up-regulated activity of the PI3K/Akt pathway is
potentially induced by elevated Igf-2 activation from
compensatory Igf-1r signaling in the fetal MIP-βIRKO

Figure 7: Working model of hyperplastic islet response observed in fetal MIP-βIRKO mice. A. The loss of insulin receptor
(IR) expression on pancreatic β-cells during 2nd transition of the pancreatic development results in enhanced secretion of insulin growth
factor-2 (Igf-2). B. Autocrine/paracrine activation of the insulin growth factor-1 receptor (Igf-1r) on pancreatic β-cell by Igf-2 promotes
Akt phosphorylation, leading to: (1) suppressed phospho-p53 (S15) activation that prevents β-cell apoptosis, and (2) increased secretion
of vascular endothelial growth factor-a (Vegf-a) through the Akt/HIF-1/Vegf-a signaling pathway in β-cells [22]. C. Together, Vegf-amediated hyper islet vascularization and upregulated Akt activity promotes exaggerated β-cell replication and cell survival, leading to an
expanded β-cell population within the pancreas of MIP-βIRKO animals.
www.impactjournals.com/oncotarget
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glucose intolerance or develop innate protection against
age-dependent islet mass degeneration [9, 11]. We utilized
multiple protocols to produce and maintain viable neonatal
offspring after intraperitoneal tamoxifen administration
at e13 to pregnant mothers, but all attempts were largely
unsuccessful due to pup rejection or non-viable progeny.
Thus, a later time-point for the temporal induction of
β-cell IRKO in pregnant mothers will be required.
In summary, this is the first study to temporally
knock out the β-cell IR during the 2nd transition phase
of pancreatic endocrine development. Fetal MIP-βIRKO
pancreata displayed an enlarged islet size and increased
β-cell area that is likely associated with the observation
of high β-cell proliferation in response to increased islet
vascularization. Furthermore, we have demonstrated that
fetal MIP-βIRKO is accompanied by heightened Igf-2/Igf1r signaling, presumably leading to the activation of Akt
and subsequent proliferation and enriched islet vasculature
via increase of Vegf-a. Taken together, an understanding
of the physiological function of insulin signaling on
fetal β-cells is crucial for preventing abnormal islet
development in utero and fine-tuning the niche for optimal
in vivo survival of β-cells.

pancreas (Figure 7). Previous research suggests the IR
and Igf-1r can compensate for one another since mice
lacking both receptors specifically in β-cells died from
diabetic ketoacidosis within 4-8 weeks [32]. In vitro β-cell
IRKO experiments support this study’s observations with
compensatory increase in Igf-1r levels [33]. Similarly,
an Igf-2 compensatory response to in vivo β-cell IR loss
is logical since Igf-2 levels are higher than Igf-1 during
fetal development and its expression is strongly localized
to islets [16]. Igf-2 is important for promoting islet cell
hyperplasia and apoptosis inhibition, which would account
for the changes seen in fetal MIP-βIRKO pancreata.
Our findings of reduced phospho-p53 (S15) in the MIPβIRKO pancreas, relative to controls, corroborates
with our observation of upregulated active Akt in MIPβIRKO pancreas as Akt is often correlated with decreased
downstream p53 activity (Figure 7). Since active p53 is
critical for cell cycle arrest and DNA repair as well as
apoptosis in response to DNA damage, we speculate that
impaired regulation of cell cycle arrest and subsequent
DNA repair could be important for increased β-cell
proliferation seen in MIP-βIRKO pancreata [34, 35].
Furthermore, this mechanism could potentially account for
the β-cell atrophy that has been observed in adult βIRKO
mice [11].
Our findings are consistent with studies in
congenital insulin knockout mice that show increased islet
proliferation and islet vascularization during fetal pancreas
development [12]. MIP-βIRKO pancreata demonstrated a
significant increase in the percent of PECAM-1+ area and
islet capillary density, and higher Vegf-a protein levels.
This data matches our observation of enhanced Igf-2 levels
in MIP-βIRKO pancreata, as vascular endothelial growth
factor (Vegf) can be upregulated by Igf-2 expression
[36]. Igf-2 acts as a stimulatory ligand of both the Igf1r and IR, and is therefore a critical factor for expansion
of β-cell mass [37-39] and embryonic vasculogenesis by
up-regulating Vegf levels via the Akt signaling pathway
(Figure 7) [40]. Our recent study further determined that
Vegf-a synthesis and secretion in the β-cell is regulated
by the Akt/mTOR pathway, through increased HIF1 expression, and is associated with increased β-cell
mass and proliferation [22]. Since the endothelium and
its associated blood supply are critical for maintenance
of β-cell fate and proliferation, numerous studies have
proposed that increased islet vascularization could result
in enhanced β-cell replication through rapid and efficient
exchange of nutrients and hormones [12, 41-44]. In
fact, short-term β-cell specific Vegf-a overexpression
in mice resulted in pancreatic islet hypervascularization
simultaneous with increased β-cell proliferation [44].
It is important to note that Igf-2 levels rapidly diminish
after birth in rodents, thus further studies are needed to
examine whether the increased islet growth seen in fetal
MIP-βIRKO pancreas can be sustained in postnatal life
and to determine whether these mice acquire postnatal
www.impactjournals.com/oncotarget

materials and METHODS
Generation of inducible β-cell specific insulin
receptor knockout mice (MIP-βIRKO)
B6.129S4(FVB)-Insrtm1Khn/J (IRfl/fl) and Tg(Ins1-Cre/
ERT)1Lphi (MIP-CreER) were obtained from the Jackson
Laboratories (Bar Harbor, MA, USA; stock number:
006955) and Dr. Louis Philipson’s laboratory (University
of Chicago, Chicago, IL, USA) [18], respectively. MIPCreER and IRfl/fl mice were crossed at our facilities. The
resulting MIP-CreER:IRfl/+ mice were timely mated
to generate experimental fetal groups. All mice were
provided ad libitum access to both food and water. All
animal use protocols were approved by the Animal Use
Subcommittee at Western University in accordance with
the Canadian Council of Animal Care.
Tamoxifen (Sigma; St. Louis, MO, USA) was
prepared by dissolving in ethanol and suspending in corn
oil (Sigma). A single dose of 6mg/40g body weight was
administered by i.p. injection to pregnant mice at e13
(Figure 1A). At e19-20, pregnant mice were euthanized
and immediately dissected to obtain the fetal tail for
genotyping and pancreas for protein extraction and
morphological analyses. Isolated fetuses were measured
for body weight and blood glucose, and genotype was
determined using PCR primers for the Insrtm1Khn mutation
and the MIP-CreER promoter (listed in Supplementary
Table 1). Experimental MIP-βIRKO (MIP-CreER+;IRfl/
fl
) mice were MIP-CreER+ (268bp) with both IR alleles
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floxed by loxP sites (IRfl/fl, 313bp). Control animals
included MIP-CreER- with IR alleles floxed (MIP-CreER;IRfl/fl) and MIP-CreER+ with IR wild-type (IR+/+, 279bp)
(MIP-CreER+;IR+/+). We confirmed that the phenotypes of
MIP-CreER-;IRfl/fl and MIP-CreER+;IR+/+ were virtually
identical in terms of islet morphology measurements.

Fetal pancreas, muscle, liver, and brain tissues
were sonicated in Nonidet-P40 lysis buffer. Protein
lysates were separated by 5-15% SDS-PAGE and were
wet transferred to a nitrocellulose membrane (Bio-Rad
Laboratories; Mississauga, ON, Canada), then incubated
with appropriately diluted primary (Supplementary Table
2) and secondary horseradish peroxidase-conjugated
secondary antibodies. Proteins were visualized with
Western Lightning Plus-Enhanced Chemoluminescence
reagents (PerkinElmer; Waltham, MA, USA). All images
were recorded using a Versadoc Imaging System (BioRad Laboratories). Densitometric analyses of images
were performed at subsaturation levels with Image Lab
3.0 software (Bio-Rad Laboratories) and normalized to
appropriate loading controls.

ELISA assay for insulin
Fetal blood plasma and pancreata were collected
at e19-20 from control and MIP-βIRKO mice. Blood
was collected from fetal mice by decapitation and
exsanguination immediately after the mother was
sacrificed. Pancreatic insulin was extracted by acidethanol extraction buffer and homogenized. Both plasma
and pancreatic insulin content were measured using an
ultrasensitive (mouse) insulin ELISA kit (ALPCO, Salem,
NH). Plasma insulin level was expressed as ng per ml, and
pancreatic insulin content was normalized to protein and
expressed as ng per mg protein [22].

Statistical analyses
Statistical analyses were performed using either
one-way ANOVA and Bonferonni’s multiple comparison
tests or Student’s unpaired t-test with GraphPad Prism
6 (GraphPad Software; La Jolla, CA, USA). Data is
presented as means ± SEM. Differences in results were
considered statistically significant when p < 0.05.

Tissue processing, immunostaining, and TUNEL
Dissected fetal pancreata were fixed in 4%
paraformaldehyde and embedded in paraffin as previously
described [22]. Sections (2-4µm thick) were prepared
and stained with appropriately diluted primary antibodies
(Supplementary Table 2), and detected using fluorescentlylabeled secondary antibodies (Jackson Immunoresearch
Laboratories; West Grove, PA, USA). Nuclei were
counterstained with DAPI (Sigma-Aldrich; St. Louis,
MO, USA). Islet Igf-1, Igf-1r, Igf-2 and V-maf avian
musculoaponeurotic fibrosarcoma oncogene homolog A
(MafA) levels were determined by immunohistochemical
staining using the streptavidin-biotin horseradish
peroxidase complex and developed with aminoethyl
carbazole substrate kit (Invitrogen, Burlington, ON,
Canada). Apoptotic β-cells (insulin+) were identified by
the terminal deoxynucleotidyl transferase dUTP nick
end-labeling (TUNEL) assay using an In Situ Cell Death
Detection Kit (Roche Applied Science, Quebec City, QC,
Canada).
Images of tissue sections were captured and islet
morphologies were blindly analyzed with Image-Pro Plus
software (Media Cybernetics; Rockville, MD, USA) for
islet density, total islet area, islet sizes, and total α-cell or
β-cell area. Islet vasculature including platelet endothelial
cell adhesion molecule-1+ (PECAM-1) area per islet, islet
capillary density and average islet capillary size were
measured [22]. An islet was defined as a dense cell cluster
containing at least 3 insulin+ cells and a glucagon+ cell
[45]. Co-localization of Ki67, transcription factors, or
Glut2 with insulin+ cells were also determined by double
immunofluorescence or immunohistochemical staining
[22].
www.impactjournals.com/oncotarget
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